

TABLE OF CONTENTS

July 27, 2009

No. 2149

BUSINESS

- 1 Immunology/Inflammation MTPC's 3rd Top-Priority Field
 - Considering Independent Marketing for 2 Nephrology Products in the US
 - Aiming at Top-Four Position through M&As in Generics Business
- 2 Hisamitsu to Acquire Noven Pharm. to Strengthen US Business Platform
 - Important Investment to Ensure Further Growth
 - Noven President Peter Brandt to Leave
- 3 Merck Serono Aims at Becoming No. 1 in Reproductive Health, Metabolic Oncology
- 4 Cravit No. 1 on HP Market, No. 2 on GP Market: Rep Track Survey
- 4 Patients, Doctors Remain Calm Despite EASD Reports on Lantus: sanofi-aventis
- 6 **BUSINESS NEWS IN BRIEF**
 - Celgene to Independently Market Revlimid
 - Merck Acquires Betrixaban from Portola
 - Bristol-Myers Recommence Supply of Kenacort-A
 - Elmed Eisai Acquires Ménière's Disease Drug from Sanwa Kagaku
 - Tella Licenses Imax to Ehime Univ.
 - EPS to Strengthen EDC Services
 - NS-ELEX, Acre Japan to Comarket EDC System

REGULATORY

- 8 Question Raised Again on Need for Exceptional Price Maintenance System
- 8 DPO Proposes New Pricing Rule for Combination Drugs
- 9 Points at Issue Proposed by *Koroshio* Regarding NHI Price Maintenance System
- 13 NDA for Sitagliptin to Be Reviewed
- 13 **REGULATORY NEWS IN BRIEF**
 - Iressa Granted Marketing Approval in the EC
 - Alimta Approved for Maintenance Therapy for NSCLC in US
 - Pediatric Data on Flomax Submitted in the US
 - Monitor Contract Manufacturers to Prevent Production of Counterfeit Drugs
 - Restrictions to Be Relaxed for Use of Cow-Derived Materials from Canada
 - PMDA Posts Information on Proper Use of Lantus on Its Website

- PhRMA Welcomes US Statement Opposing Market-Expansion Repricing

COMMENTARY

- 16 **Maurer's Healthcare Insight (110)**
 - I Am Losing It: P. Reed Maurer
- 17 **Statistics**
 - Sales of Ethical Drugs Down 1.6% in May: Crecon

GENERICS

- 18 NHI Price Listing Expected for 46 Generics for Sarpogrelate from 23 Companies
 - Some New Dosage Forms Not Available with Original Products
- 18 Nichi-Iko to Enter US Market in 2012
 - Domestic Market for Generics Not Growing as Fast as Expected
 - Sales Up 45% due to Acquisition of Teikoku Medix
- 19 Nat'l Univ. Hospitals Apprehensive of Negative Effects of Use of Generics on Their Research

R&D

- 20 *Koroshio* to Build Up Network of Global Clinical Research Centers
- 20 **R&D NEWS IN BRIEF**
 - Takeda Begins Construction of New Research Facilities
 - Everolimus Shrinks Pancreatic NET: Novartis

MEDICAL FACILITIES & NURSING CARE

- 22 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - Gaster Inhibits GI Ulcers due to Low-Dose Aspirin
 - Product Labeling for Champix Is Inadequate: YAKUGAI Ombudsperson
 - *Koroshio* to Cut Number of Patients Admitted for Schizophrenia by 46,000
 - Pharm. Association Merges with Association of Hospital-based Pharmacists in Kyoto
 - Number of DPC Hospitals Up to 1,283

SELF-MEDICATION

- 23 **SELF-MEDICATION NEWS IN BRIEF**
 - Zeria Launches Additional OTC Versions of Acinon